| Drug General Information |
| Drug ID |
D00EHX
|
| Former ID |
DIB010281
|
| Drug Name |
TT-301
|
| Synonyms |
Minozac; MW01-9-034WH; Anti-neuroinflammatories (Alzheimer's disease), NeuroMedix/Transition Therapeutics
|
| Indication |
Alzheimer disease [ICD9: 331; ICD10:G30]
|
Phase 1 |
[1]
|
|---|
| Company |
Northwestern University
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Canonical SMILES |
c1nc(ncc1)N1CCN(CC1)c1c(cc(nn1)c1ccccc1)C.Cl.Cl
|
| CAS Number |
CAS 924909-75-1
|
| Target and Pathway |
| Target(s) |
Interleukin-1 beta |
Target Info |
Inhibitor |
[2]
|
|---|
|
KEGG Pathway
|
MAPK signaling pathway
|
|
Cytokine-cytokine receptor interaction
|
|
NF-kappa B signaling pathway
|
|
Apoptosis
|
|
Osteoclast differentiation
|
|
Toll-like receptor signaling pathway
|
|
NOD-like receptor signaling pathway
|
|
Cytosolic DNA-sensing pathway
|
|
Hematopoietic cell lineage
|
|
TNF signaling pathway
|
|
Inflammatory mediator regulation of TRP channels
|
|
Non-alcoholic fatty liver disease (NAFLD)
|
|
Type I diabetes mellitus
|
|
Alzheimer's disease
|
|
Prion diseases
|
|
Salmonella infection
|
|
Pertussis
|
|
Legionellosis
|
|
Leishmaniasis
|
|
Chagas disease (American trypanosomiasis)
|
|
African trypanosomiasis
|
|
Malaria
|
|
Amoebiasis
|
|
Tuberculosis
|
|
Measles
|
|
Influenza A
|
|
Herpes simplex infection
|
|
Inflammatory bowel disease (IBD)
|
|
Rheumatoid arthritis
|
|
Graft-versus-host disease
|
|
NetPath Pathway
|
Leptin Signaling Pathway
|
|
IL5 Signaling Pathway
|
|
IL1 Signaling Pathway
|
|
IL2 Signaling Pathway
|
|
IL3 Signaling Pathway
|
|
TGF_beta_Receptor Signaling Pathway
|
|
Wnt Signaling Pathway
|
|
TCR Signaling Pathway
|
|
TNFalpha Signaling Pathway
|
|
Pathway Interaction Database
|
IL27-mediated signaling events
|
|
IL12-mediated signaling events
|
|
IL1-mediated signaling events
|
|
IFN-gamma pathway
|
|
IL23-mediated signaling events
|
|
Cellular roles of Anthrax toxin
|
|
Reactome
|
Interleukin-1 signaling
|
|
Interleukin-1 processing
|
|
CLEC7A/inflammasome pathway
|
|
WikiPathways
|
Toll-like receptor signaling pathway
|
|
Monoamine Transport
|
|
SIDS Susceptibility Pathways
|
|
TCR Signaling Pathway
|
|
Type II interferon signaling (IFNG)
|
|
Senescence and Autophagy in Cancer
|
|
Cytokines and Inflammatory Response
|
|
MAPK Signaling Pathway
|
|
Myometrial Relaxation and Contraction Pathways
|
|
Aryl Hydrocarbon Receptor Pathway
|
|
IL1 and megakaryotyces in obesity
|
|
Hematopoietic Stem Cell Differentiation
|
|
Spinal Cord Injury
|
|
Allograft Rejection
|
|
Alzheimers Disease
|
|
Leptin signaling pathway
|
|
IL-1 signaling pathway
|
|
Interleukin-1 signaling
|
|
Folate Metabolism
|
|
Vitamin B12 Metabolism
|
|
Selenium Micronutrient Network
|
|
Serotonin Transporter Activity
|
|
Regulation of toll-like receptor signaling pathway
|
|
NOD pathway
|
| References |
| REF 1 | ClinicalTrials.gov (NCT01357421) Effects of TT301 on Cytokine Levels Post Endotoxin Challenge. U.S. National Institutes of Health. |
|---|
| REF 2 | A Swell in the Armamentarium of Antiepileptic Drug Targets. Epilepsy Curr. 2011 Nov-Dec; 11(6): 172-176. |
|---|
